ASRT

Sig Kirk Joins Assertio Board of Directors

Retrieved on: 
Wednesday, April 3, 2024
AbbVie, Financial management, Certification, Barr Pharmaceuticals, Audit, Business administration, Patient, Pace University, ASRT, Compensation, Allergan, CPA

LAKE FOREST, Ill., April 03, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced effectiveness of the appointment of Sigurd (Sig) Kirk to its board of directors.

Key Points: 
  • LAKE FOREST, Ill., April 03, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced effectiveness of the appointment of Sigurd (Sig) Kirk to its board of directors.
  • Kirk is a senior corporate business development executive with more than 20 years of pharmaceutical experience in the areas of branded biopharmaceutical, medical device and generic products.
  • Mr. Kirk started his career at Deloitte & Touche as an Audit Manager, earning his CPA certification.
  • “Both Sig’s appointment and the addition of Sravan Emany last fall demonstrate our ongoing commitment to aligning our board expertise with our evolving business strategies.”

Assertio to Present at LD Micro Invitational Conference in New York City

Retrieved on: 
Monday, April 1, 2024
Patient, Conference, ASRT, Software

LAKE FOREST, Ill., April 01, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that Ajay Patel, Chief Financial Officer, will present at the LD Micro Invitational XIV Conference to be held April 9, 2024 in New York City.

Key Points: 
  • LAKE FOREST, Ill., April 01, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that Ajay Patel, Chief Financial Officer, will present at the LD Micro Invitational XIV Conference to be held April 9, 2024 in New York City.
  • The Company will host a group presentation at 4:00 pm Eastern Time, and be available for individual meetings throughout the day.
  • Attending investors interested in meeting with the Company can request a meeting on the conference platform, or contact Assertio investor relations via [email protected] .
  • Presentation information will be available on the day of the event and can accessed at https://investor.assertiotx.com .

ASSERTIO ALERT: Bragar Eagel & Squire, P.C. is Investigating Assertio Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, March 28, 2024
Rheumatoid arthritis, Learning, EPS, Risk, Telephone, Patient, Suppository, Sale, Acquisition, News, ASRT, Complaint, Adjustment, P.C, Spectrum, Spectrum Pharmaceuticals, FDA, Food, Cryptocurrency

Our investigation concerns whether the board of directors of Assertio have breached their fiduciary duties to the company.

Key Points: 
  • Our investigation concerns whether the board of directors of Assertio have breached their fiduciary duties to the company.
  • Assertio is a commercial pharmaceutical company that purportedly offers differentiated products to patients utilizing a non-personal promotional model.
  • One of the Company's primary pharmaceutical products is Indocin, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis.
  • Then, on November 8, 2023, Assertio issued a press release announcing its financial results for its third quarter ("Q3") of 2023.

GE HealthCare Announces the FDA Clearance of nCommand Lite by IONIC Health

Retrieved on: 
Monday, March 25, 2024
Mobile, Wireless, Technology, Medical Devices, FDA, Health Technology, Software, Hardware, Radiology, Health, Data Management, PET/CT, Lite, Patient, ASRT, Workflow, GE HealthCare, Society, Digital Solutions, Radiographer, Medical imaging

GE HealthCare (Nasdaq: GEHC) announces the U.S. FDA 510(k) Clearance of IONIC Health’s nCommand Lite technology.

Key Points: 
  • GE HealthCare (Nasdaq: GEHC) announces the U.S. FDA 510(k) Clearance of IONIC Health’s nCommand Lite technology.
  • IONIC Health’s nCommand Lite includes multi-modality capabilities in support of magnetic resonance (MR), computed tomography (CT), and positron emission tomography/CT (PET/CT) scanning.
  • To further enhance its remote operations portfolio, GE HealthCare launched an FDA-cleared new version of Digital Expert Access and announced an exclusive distribution agreement with IONIC Health in November 2023.
  • “We are thrilled that our nCommand Lite solution, built on the three-year-strong nCommand platform from Brazil, is now cleared for use in the U.S.,” said José Leovigildo Coelho, CEO and co-founder of IONIC Health.

March 5, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against ASRT

Retrieved on: 
Tuesday, March 5, 2024
Acquisition, Court, NEXT, Telephone, COST, Sale, Risk, CLASS, Spectrum Pharmaceuticals, LLP, ASRT, Cryptocurrency

NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Assertio Holdings, Inc. ("Assertio Holdings" or the "Company") (NASDAQ: ASRT) of a class action securities lawsuit.

Key Points: 
  • NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Assertio Holdings, Inc. ("Assertio Holdings" or the "Company") (NASDAQ: ASRT) of a class action securities lawsuit.
  • Follow the link below to get more information and be contacted by a member of our team:
    ASRT investors may also contact Joseph E. Levi, Esq.
  • WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

Assertio Holdings, Inc. Investors: Company Investigated by the Portnoy Law Firm

Retrieved on: 
Monday, March 4, 2024
Acquisition, FDA, News, Food, Zydus Lifesciences, Suppository, ASRT

LOS ANGELES, March 04, 2024 (GLOBE NEWSWIRE) -- ​The Portnoy Law Firm advises Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) investors that the law firm has initiated an investigation on behalf of investors that lost money on their Assertio stock. Assertio investors are encouraged to contact the firm to discuss their legal rights.

Key Points: 
  • LOS ANGELES, March 04, 2024 (GLOBE NEWSWIRE) -- ​ The Portnoy Law Firm advises Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) investors that the law firm has initiated an investigation on behalf of investors that lost money on their Assertio stock.
  • Assertio investors are encouraged to contact the firm to discuss their legal rights.
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
  • The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing.

DEADLINE TOMORROW: Berger Montague Advises Assertio Holdings (NASDAQ: ASRT) Investors to Inquire About a Securities Fraud Class Action by March 5, 2024

Retrieved on: 
Monday, March 4, 2024
Attention, Court, FDA, News, Food, Lead, Rheumatoid arthritis, Patient, ASRT, The, Cryptocurrency

A securities fraud class action lawsuit has been filed against Assertio on behalf of purchasers of Assertio’s securities between March 9, 2023 and November 8, 2023, inclusive (the “Class Period”).

Key Points: 
  • A securities fraud class action lawsuit has been filed against Assertio on behalf of purchasers of Assertio’s securities between March 9, 2023 and November 8, 2023, inclusive (the “Class Period”).
  • Important deadline: Investors who purchased or acquired Assertio securities during the Class Period may, no later than March 5, 2024, seek to be appointed as a lead plaintiff representative of the class.
  • Berger Montague , with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco and Chicago, has been a pioneer in securities class action litigation since its founding in 1970.
  • Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Assertio Holdings, Inc. (ASRT)

Retrieved on: 
Friday, March 1, 2024
GPM, Acquisition, Court, Suite, Spectrum, News, Food, Sale, Risk, Suppository, ASRT, Defendant, Cryptocurrency

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • On this news, Assertio’s stock price fell $2.44, or 45.6%, to close at $2.91 per share on August 4, 2023, thereby injuring investors.
  • Then, on January 3, 2024, Assertio announced that its CEO was stepping down from his role at the Company.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Maison Solutions, Assertio, Dada, and Cummins and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, March 1, 2024
Nexus, Complaint, Acquisition, Prospectus, Register, Spectrum, Dada, Marketing, FDA, News, Food, Sale, CMI, Form, Adjustment, Risk, Learning, IPO, Suppository, Rheumatoid arthritis, Spectrum Pharmaceuticals, Patient, ASRT, EPS, P.C, Audit

For more information on the Maison Solutions class action go to: https://bespc.com/cases/MSS

Key Points: 
  • For more information on the Maison Solutions class action go to: https://bespc.com/cases/MSS
    Assertio is a commercial pharmaceutical company that purportedly offers differentiated products to patients utilizing a non-personal promotional model.
  • One of the Company's primary pharmaceutical products is Indocin, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis.
  • According to the complaint, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • For more information on the Cummins class action go to: https://bespc.com/cases/CMI

Assertio Holdings, Inc. to Release Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024

Retrieved on: 
Thursday, February 29, 2024
ASRT, ID, Webcast, Patient, Software, Telephone

Following the release of its financial results, Assertio’s management will host a live webcast of the earnings conference call at 4:30 p.m. Eastern Time.

Key Points: 
  • Following the release of its financial results, Assertio’s management will host a live webcast of the earnings conference call at 4:30 p.m. Eastern Time.
  • To access the live webcast, conference call information, and other materials, please visit Assertio’s investor relations website at http://investor.assertiotx.com/overview/default.aspx .
  • Please connect at least 10 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast.
  • A webcast replay of the call will be available approximately two hours after the call on Assertio’s investor website.